



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445, 9/00, 47/18 // (A61K 31/445, 31:135)	A1	(11) International Publication Number: WO 99/62516 (43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/US99/10469 (22) International Filing Date: 27 May 1999 (27.05.99) (30) Priority Data: 09/088,128 1 June 1998 (01.06.98) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: MUNAYYER, Farah, J.; 494 Passaic Avenue, West Caldwell, NJ 07006 (US). GUAZZO, Frank; 920 Ardsley Lane, Bridgewater, NJ 08807 (US). STUPAK, Elliot, I.; 11 Woodland Road, West Caldwell, NJ 07006 (US). CHAUDRY, Imtiaz, A.; 18 Rose Avenue, North Caldwell, NJ 07006 (US). SEQUEIRA, Joel, A.; 6 Mary Ellen Drive, Edison, NJ 08820 (US). (74) Agents: FRANKS, Robert, A. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A STABILIZED ANTIHISTAMINE SYRUP CONTAINING AMINOPOLYCARBOXYLIC ACID AS STABILIZER		
(57) Abstract <p>An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

A STABILIZED ANTIHISTAMINE SYRUP CONTAINING AMINOPOLYCARBOXYLIC ACID AS STABILIZER

15

INTRODUCTION TO THE INVENTION

The present invention pertains to the field of liquid pharmaceutical formulations, and more particularly to syrup formulations containing antihistamines.

Syrup formulations are commonly used for delivery of pharmacological agents, particularly where the agents are to be delivered to pediatric patients. Traditional syrups are concentrated solutions of sugar (generally sucrose) in purified water, such as Syrup, NF prepared with 850 grams sucrose and sufficient water to make 1000 mL according to the procedure given in the official monograph at page 1990 of *NF XVII The National Formulary*, United States Pharmacopeial Convention, Inc., Rockville, Maryland U.S.A., 1990. However, for purposes of the present invention, the term "syrup" will also encompass those liquid formulations having a sweet taste provided wholly or partly by artificial sweeteners, such as saccharin, sorbitol, aspartame, sodium cyclamate and the like, for avoidance of dental and medical problems which may be aggravated by higher caloric sweeteners. As is well appreciated in the art, syrups frequently are flavored, such as with fruit or mint flavors, usually for purposes of masking an unpleasant taste caused by the presence of a dissolved or suspended pharmacologically active substance. A pleasant taste is particularly important when the formulation is intended for ingestion by children. Typical flavoring agents which are commonly used in

sweetened pharmaceuticals, foods, candies, beverages and the like are also useful in the present invention; these materials impart flavors such as grape, cherry, citrus, peach, strawberry, bubble gum, peppermint and many others.

Syrups frequently must contain antimicrobial components to ensure
5 safe storage without the proliferation of pathogenic molds, yeasts, bacteria and the like; a typical antimicrobial deemed suitable for use in foods and other ingestible substances is sodium benzoate. In addition, those syrups which do not contain sugar, or which contain a mixture of sugar and another sweetener, may contain thickening agents (such as a hydroxypropyl
10 methylcellulose, some forms of which are available from Dow Chemical, Midland, Michigan USA under the METHOCEL trademark) to provide a viscous mouth-feel similar to that of a traditional syrup.

An example of a currently marketed syrup contains 1 mg/mL of the antihistaminic drug loratadine, together with citric acid, artificial flavor,
15 glycerin, propylene glycol, sodium benzoate, sucrose and water; this formulation typically has a pH value between about 2 and 4. However, under certain storage conditions involving contact with the air, losses of loratadine content, and a concomitant generation of impurities, have occurred. Similar problems can occur with formulations containing other, chemically related,
20 drugs, such as descarboethoxyloratadine and azatadine.

J. S. Nairn, "Solutions, Emulsions, Suspensions and Extracts," Chapter 83 in A.R. Gennaro, Ed., *Remington's Pharmaceutical Sciences*, 18th Ed., Mack Publishing Co., Easton Pennsylvania U.S.A., 1990 at pages 1519-1520 discusses the problem of active agent stability in aqueous media. It is
25 stated that trace metal-initiated oxidation reactions can be minimized through the use of citric acid or EDTA sequestering agents.

It is desired to provide a storage-stable syrup formulation of loratadine or related antihistaminic components, which contains only components recognized as being safe for human ingestion.


SUMMARY OF THE INVENTION

In accordance with the invention, there is provided a syrup formulation containing loratadine or a chemically related antihistamine, including any pharmaceutically acceptable salt thereof, together with a stabilizing amount of an aminopolycarboxylic acid. Suitable aminopolycarboxylic acids include ethylenediaminetetraacetic acid ("EDTA") and salts thereof, such as the disodium salt. The acid or salt is usually present in the formulation in concentrations about 0.05 mg/mL to about 5 mg/mL.


10

DETAILED DESCRIPTION OF THE INVENTION


Loratadine is the drug name given to the compound known as ethyl 4-(8-chloro-5,6-dihydro-11*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridin-11-ylidene)-1-piperidinecarboxylate and having the empirical formula $C_{22}H_{23}ClN_2O_2$. A structure for this compound is:



The compound descarboethoxyloratadine is an antihistaminic active metabolite of loratadine, having the following structure:



A closely related antihistamine is azatadine, having the following structural formula:



5

Degradation of syrup formulations containing loratadine or related antihistamines is observed during storage stability testing, as evidenced by declining concentrations of the active ingredient and a concomitant formation of impurities. Two of the impurities which form in loratadine syrups have been identified as 2-Hydroxymethyl loratadine ("2-HML") and 4-Hydroxymethyl loratadine ("4-HML"), while other unidentified impurities occur regularly and have been collectively denoted as "Group A"; these materials number about 5 to 7 and elute together in an HPLC analysis, at retention times which indicate a higher polarity than that of loratadine. The severity of the degradation may be at least approximately related to the volume in a product bottle which is not filled with syrup, i.e., the "headspace." As it is not practical to fill each bottle completely to the top, a test has been conducted where the headspace was filled with nitrogen gas; results were inconclusive, possibly due to the unavoidable oxygen permeability of the polymeric bottle closure.

Another test was conducted, wherein common antioxidant additives were incorporated into the syrup. Ideally, the antioxidant will be soluble in the syrup and is safe for use in foods and pharmaceutical preparations. Among the water-soluble materials, ascorbic acid at 0.1 and 1 mg/mL was found to somewhat reduce degradation, but also caused an unacceptable strong color change in the product, while sodium bisulfite imparted a pungent, disagreeable odor to the syrup. The oil-soluble antioxidants butylated hydroxytoluene and tocopherol were not soluble in the syrup, so also were not found acceptable.

It has been found that the addition of small amounts of an aminopolycarboxylic acid, the term specifically including salts of the acids, can stabilize the syrups against degradation. Useful aminopolycarboxylic acids and salts thereof are those which are safe for ingestion and have sufficient solubility in the syrup formulations to make a stable single phase composition. Commercially available compounds which could be used include iminodiacetic acid, methyliminodiacetic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid ("EDTA"), diethylenetriaminepentaacetic acid, 1,2-diaminocyclohexane-tetraacetic acid, N-hydroxyethylenediaminetriacetic acid and related compounds. Mixtures of two or more of the foregoing are suitable for use. From the aspects of ready availability, safety, efficacy and cost, the alkali metal salts of EDTA are presently preferred, and the remainder of this description will focus on those materials.

An aminopolycarboxylic acid or salt will typically be present in a syrup at about 0.05 mg/mL to about 5 mg/mL. More preferably, the level of aminopolycarboxylic acid will be about 0.1 mg/mL to about 1 mg/mL. As with any additive component in a formulation intended for ingestion, it is desirable to incorporate the minimum level which will yield the desired result. This level can be readily determined by means of an accelerated storage stability test, in which packages of the final product are stored at elevated temperatures above the usual storage temperatures to which the product is expected to be exposed; the present inventors have used temperatures up to 55°C for this purpose, although such temperatures tend to cause a minor discoloration (darkening) of the syrups, probably due to some caramelization of the contained sucrose. It is expected that most drug degradation reactions will be accelerated by the elevated temperature. At predetermined intervals, some of the packages are opened and analyzed to determine the amount of active ingredients and impurities present in the formulation.

Antihistaminic syrup formulations frequently also contain other drugs, for obtaining more than one therapeutic result from a single dose. Typical drug substances included with the antihistamine are sympathomimetic amine decongestants, such as pseudoephedrine or phenylpropanolamine

(for relief of the upper airway congestion often accompanying disorders such as rhinitis and upper respiratory infections), and analgesics, such as aspirin, acetaminophen, ibuprofen, naproxen or ketoprofen (for relief of pain and, except in the case of acetaminophen, for reducing inflammation).

- 5 Antitussives, such as codeine, hydrocodone or dextromethorphan, for relief from coughing, and expectorants such as guaifenesin, for increasing cough productivity, also are included in combination products. Any of these additional ingredients, including salts thereof and other drugs from the same therapeutic classes, are suitable for inclusion in the syrups of the present
10 invention.

The invention will be further described by means of the following examples, which are not intended to limit the scope of the invention as defined by the appended claims. Where the term "percent" is used herein, it is intended to represent percent by weight, unless the context clearly
15 evidences otherwise.

EXAMPLE 1

A syrup was formulated to contain the following ingredients, wherein
20 amounts of all except water are expressed in milligrams.

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, micronized	1
25	Citric acid	8.78
	Flavoring agent	2.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
30	Disodium EDTA	0.25
	Sucrose	600
	Water	to make 1.0 mL

This syrup is prepared using the following procedure: (a) about 80 percent of the water is placed in a vessel, heated to 75-85°C, charged with the sugar and stirred to form a solution; (b) the citric acid is charged to the solution and stirring is continued to form a solution, then the sodium benzoate is added and dissolved; (c) the solution is cooled to 30-35°C, with continued stirring, and the disodium EDTA is added and dissolved; (d) the glycerin is added and stirring continued while the solution cools to 25-30°C; (e) in a separate vessel, the propylene glycol and loratadine are combined and stirred to form a solution (note that the use of micronized loratadine particles decreases the time required to accomplish dissolution), then the flavoring agent is added and stirred to achieve homogeneity; (f) the product of step e is combined with the product of step d, with stirring to ensure homogeneity, and sufficient water is added to provide the proper formulation weight; and (g) the resulting syrup is passed through clarifying filters. The syrup is a clear, colorless liquid (which could readily be colored as desired, such as by adding a suitable pharmaceutically acceptable water-soluble dye to the sugar solution of step a) and is denoted Sample A.

Another syrup is similarly formulated, except that it further contains 1 mg/mL of the disodium salt of EDTA. This is denoted Sample B.

Twenty five mL portions of the two syrups are placed into 50 mL flint glass vials, then sealed with rubber stoppers and aluminum caps. The sealed vials are stored at 55°C until their removal and analysis by high performance liquid chromatography. Results of the analyses are as follows, where "NQ" indicates a result below the limit of quantification (0.1%) but above the limit of detection (0.02%):

	<u>Sample</u>	<u>Storage (weeks)</u>	<u>Percent Degradation Products</u>		
			<u>2-HML</u>	<u>4-HML</u>	<u>Total</u>
5	A	3	0.23	0.19	0.42
		6	0.33	0.32	0.81 ^a
10	B	3	0.11	NQ	0.11
		6	0.10	NQ	0.10
		12	0.15	0.14	0.62 ^b

^a Sample contained 0.16% of an unidentified degradation product

^b Sample contained two unidentified degradation products at levels of 0.21% and 0.12%

15 These results indicate a significant inhibition by EDTA of the degradation of loratadine during the severe storage conditions of the test.

EXAMPLE 2

20 Sample A from the preceding example and similarly prepared syrups which also contain 0.1, 0.25, 0.5 or 0.75 mg/mL of disodium EDTA are packaged as in the prior example, and stored and tested similarly. The following results are obtained, where "ND" indicates a concentration below the limit of detection previously stated.

	<u>EDTA (mg/mL)</u>	<u>Storage (weeks)</u>	<u>Percent Degradation Products</u>		
			<u>2-HML</u>	<u>4-HML</u>	<u>Total</u>
30	0	3	0.25	0.21	0.69 ^a
		6	0.29	0.24	0.67 ^b
		9	0.49	0.53	1.54 ^c

-9-

	0.1	3	NQ	NQ	NQ
		6	0.10	NQ	0.10
		9	0.12	0.11	0.33 ^d
5	0.25	3	NQ	NQ	NQ
		6	NQ	NQ	NQ
		9	0.10	NQ	0.10
	0.5	3	NQ	ND	NQ
10		6	0.10	ND	0.10
		9	0.11	0.10	0.21
	0.75	3	NQ	NQ	NQ
		6	0.10	ND	0.10
15		9	0.10	0.10	0.20

^a Sample contained 0.11% of Group A degradation products and 0.12% of an unidentified degradation product

^b Sample contained 0.14% of an unidentified degradation product

20 ^c Sample contained three unidentified degradation products at levels of 0.17%, 0.13% and 0.22%

^d Sample contained 0.10% of an unidentified degradation product

25 These results suggest that 0.25 percent disodium EDTA would be a reasonable level for storage protection of the tested syrup.

EXAMPLE 3

30 A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

-10-

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, Micronized	1
	Citric acid	8.78
5	Flavoring agent	1.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
	Disodium EDTA	0.25
10	Coloring agent	1
	Sucrose	400
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

15

EXAMPLE 4

A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

20

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, micronized	1
25	Citric acid	0.48
	Sodium citrate	0.6
	Flavoring agent	1.5
	Glycerin	350
	Propylene glycol	100
30	Sorbitol	150
	Sodium benzoate	1
	Disodium EDTA	0.25

-11-

Sodium cyclamate	0.75
Hydroxypropyl methylcellulose	0.5
Coloring agent	1
Water	to make 1.0 mL

5

This syrup is found to exhibit acceptable storage stability.

METHOCEL™ K100M, K4M and A4M from Dow Chemical are among the hydroxypropyl methylcellulose products which are suitable for use in the invention; substituting the various available products can cause syrup viscosity changes, so experiments should be conducted to determine the appropriate grade and amount needed to prepare a given syrup with desired properties.

EXAMPLE 5

15

A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

20	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, micronized	1
	Citric acid	0.48
	Sodium citrate	0.6
25	Flavoring agent	1
	Glycerin	350
	Propylene glycol	100
	Sorbitol	150
	Sodium benzoate	1
30	Disodium EDTA	0.25
	Saccharin	0.75
	Hydroxypropyl methylcellulose	0.5

Water to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

5

EXAMPLE 6

A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

10

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine	1
	Citric acid	0.48
15	Sodium citrate	0.6
	Flavoring agent	2.5
	Glycerin	450
	Sorbitol	250
	Propylene glycol	100
20	Sodium benzoate	1
	Disodium EDTA	0.25
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

25

EXAMPLE 7

A stabilized syrup is formulated according to the previously described general procedure, but substituting descarboethoxyloratadine for loratadine, to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

30

	<u>Ingredient</u>	<u>Amount</u>
	Descarboethoxyloratadine	1
	Citric acid	8.78
5	Flavoring agent	2.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
	Disodium EDTA	0.25
10	Sucrose	400
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

15

EXAMPLE 8

A stabilized syrup is formulated according to the previously described general procedure, but substituting azatadine for loratadine, to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

20

	<u>Ingredient</u>	<u>Amount</u>
	Azatadine	1
25	Citric acid	8.78
	Flavoring agent	2.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
30	Sucrose	600
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

EXAMPLE 9

- 5 A stabilized syrup for pediatric use is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

	<u>Ingredient</u>	<u>Amount</u>
10	Loratadine	0.5
	Pseudoephedrine sulfate	3
	Acetaminophen	32
	Dextromethorphan hydrobromide	1.5
	Citric acid	8.78
15	Flavoring agent	1.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
	Disodium EDTA	0.25
20	Coloring agent	1
	Sucrose	400
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

WHAT IS CLAIMED IS:

1. An antihistaminic syrup formulation containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts thereof.
5
2. The syrup of claim 1, which contains an antihistaminic ingredient selected from the group consisting of: loratadine; descarboethoxyloratadine; azatadine; and any combination of two or more thereof.
10
3. The syrup of claim 1, which contains the antihistaminic ingredient loratadine.
4. The syrup of claim 1, which contains the antihistaminic
15 ingredient descarboethoxyloratadine.
5. The syrup of claim 1, which contains the antihistaminic ingredient azatadine.
- 20 6. The syrup of claim 1, wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more
25 thereof.
7. The syrup of claim 1, wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.
- 30 8. The syrup of claim 1, in which the aminopolycarboxylic acid comprises about 0.1 to 1 mg/mL.

9. The syrup of claim 7, in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

10. The syrup of claim 1, further containing a therapeutically effective amount of a decongestant, an analgesic, an antitussive, an expectorant, or any combination of two or more thereof.

11. The syrup of claim 1, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

12. The syrup of claim 1, further containing the decongestant pseudoephedrine.

13. The syrup of claim 12, which contains the antihistaminic ingredient loratadine.

14. An antihistaminic syrup formulation containing loratadine or descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

15. The syrup of claim 14, wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.

16. The syrup of claim 14, wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.

17. The syrup of claim 14, in which the aminopolycarboxylic acid comprises about 0.1 to 1 mg/mL.

-17-

18. The syrup of claim 14, in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

19. The syrup of claim 14, further containing an analgesic.

5

20. The syrup of claim 14, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

21. The syrup of claim 20, further containing an analgesic.

10

22. An antihistaminic syrup formulation containing loratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

23. An antihistaminic syrup formulation containing
15 descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10469

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/445 A61K9/00 A61K47/18 //(A61K31/445,31:135)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 620 001 A (MCNEIL PPC INC) 19 October 1994 (1994-10-19) claims 1,6 page 5, line 13 - line 14 examples 1-4	1-22
A	WO 98 18470 A (SCHERING CORP) 7 May 1998 (1998-05-07) page 7, line 27 claims 1-16	1-22
P, X	WO 98 24414 A (AMERICAN HOME PROD) 11 June 1998 (1998-06-11) examples 2,3	1,6-12

☐ Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 October 1999

Date of mailing of the international search report

02/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10469

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0620001 A	19-10-1994	CA 2121435 A	17-10-1994
		FI 941777 A	17-10-1994
		NO 941358 A	17-10-1994
		US 5658919 A	19-08-1997
WO 9818470 A	07-05-1998	AU 4995397 A	22-05-1998
		EP 0941091 A	15-09-1999
		NO 992062 A	29-04-1999
WO 9824414 A	11-06-1998	US 5759579 A	02-06-1998
		AU 7622498 A	29-06-1998
		EP 0944383 A	29-09-1999

THIS PAGE BLANK (USPTO)